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Purpose: This study was conducted to perform a comparative analysis of the efficacy 
and safety of conventional transurethral resection of the prostate (TUR-P), transure-
thral resection in saline (TURIS), and TURIS-plasma vaporization (TURIS-V) when 
performed by a single surgeon for benign prostatic hyperplasia (BPH). 
Materials and Methods: The clinical data of 73 consecutive men who underwent conven-
tional TUR-P (39), TURIS (19), or TURIS-V (15) for BPH were retrospectively analyzed. 
All procedures were carried out by a single surgeon between October 2007 and April 
2010. The patients were assessed preoperatively and perioperatively and were followed 
at 1, 3, and 6 months postoperatively. Patient baseline characteristics, perioperative 
data, and postoperative outcomes were compared, and major complications were 
recorded.
Results: In all groups, significant improvements in subjective and objective voiding pa-
rameters were achieved and were sustained throughout follow-up. TURIS-V had the 
shortest operation time compared with conventional TUR-P and TURIS (p=0.211). 
TURIS-V significantly decreased procedural irrigation fluid volume, postoperative ir-
rigation duration, catheter duration, and hospital stay compared with conventional 
TUR-P and TURIS. There were no significant differences between the groups in hemo-
globin levels or serum sodium levels before and after the operations. There were three 
transfusions and four clot retentions in the TUR-P group, and one transfusion and one 
clot retention in the TURIS group. The TURIS-V group had no complications.
Conclusions: TURIS and TURIS-V were effective for the surgical treatment of BPH in 
addition to conventional TUR-P. TURIS-V was not inferior to conventional TUR-P or 
TURIS in terms of safety.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the most com-
mon diseases in Korean men of middle age and older. The 
prevalence of clinical BPH in a community-based study of 
Chungbuk province was 27.7% with use of the definition 
of BPH of a prostate volume ≥20 ml and an International 
Prostate Symptom Score (IPSS) ≥8 [1]. BPH frequency 
and importance are rising, owing to gradual changes in life-
style and rapid increases in the elderly population [2]. 
Although benign, this disease has a progressive evolution 
and has a negative impact on the health-related quality of 
life of the patients, marked by obstructive and irritative 
lower urinary tract symptoms (LUTS) [3]. Korean J Urol 2011;52:763-768
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Transurethral resection of the prostate (TUR-P) is the 
most effective surgical modality for symptomatic BPH [4]. 
According to the European Association of Urology 
Guidelines 2009, monopolar TUR-P is the treatment of 
choice for prostates of 30 to 80 ml [5]. However, post-
operative morbidity after TUR-P is significant. TUR-P can 
result in complications such as postoperative bleeding, 
urethral stricture, urinary incontinence, retrograde ejacu-
lation, and transurethral resection (TUR) syndrome. In 
particular, complications causing hemorrhage lead to de-
layed hospital discharge and possible blood transfusion [6]. 
In the past decade, several technologies have been devel-
oped to treat BPH with minimal risks and acceptable 
efficacy. Currently, approximately 30% of patients who are 
admitted for surgery have concomitant cardiovascular dis-
eases and ongoing anticoagulant therapy; this is respon-
sible for an increased risk of hemorrhagic complications 
[4,7]. The use of bipolar electrosurgical technology, name-
ly, transurethral resection of the prostate in saline 
(TURIS), has shown fewer complications and comparable 
results to standard TUR-P in early and short follow-ups [8]. 
Additionally, the use of 0.9% saline as the irrigation fluid 
has greatly reduced the risk of TUR syndrome, owing to re-
duced fluid absorption [9]. Recently, a new development of 
this technique, the TURIS-plasma vaporization (TURIS-V) 
technique, which uses the Olympus UES-40 Surgmaster 
generator (Olympus, Tokyo, Japan) and ‘mushroom’ va-
po-resection electrode, was introduced in clinical practice.
In the present study, we aimed to evaluate and compare 
the efficacy and safety of conventional TUR-P, TURIS, and 
TURIS-V for the treatment of BPH when carried out by a 
single surgeon.
MATERIALS AND METHODS 
We retrospectively analyzed the clinical data of 73 consec-
utive men who underwent conventional TUR-P (39 cases), 
TURIS (19 cases), or TURIS-V (15 cases) for the treatment 
of BPH. All procedures were carried out by a single surgeon 
(JHH) between October 2007 and April 2010. All patients 
underwent history taking, physical examination, trans-
rectal ultrasonography, and a blood test for prostate-spe-
cific antigen (PSA) before surgery. Patients with palpable 
nodules on the digital rectal exam or with PSA levels great-
er than 3 ng/ml before surgery underwent prostate tissue 
biopsy to assess for prostate cancer. Those diagnosed with 
prostate cancer were excluded from the study. Patients 
showing a neurogenic bladder in the urodynamic studies, 
those with urinary tract infection or urethral stricture, and 
those with previous prostate surgery, chronic renal failure, 
or receiving anticoagulant therapy were also excluded. 
Those with an American Society of Anesthesiologists clas-
sification of 2 or less were included, but all patients dis-
continued anticoagulant agents for 2 weeks before surgery. 
Indications for surgery were an IPSS of 12 points or more 
before surgery and a maximal urinary flow rate (Qmax) 
lower than 15 ml/s. All patients were assessed pre-
operatively and perioperatively and were followed at 1, 3, 
and 6 months postoperatively. The preoperative and post-
operative parameters included IPSS, quality of life (QoL), 
prostate volume, serum PSA levels, maximal urinary flow 
rates, and post-voiding residual urine volume. Periopera-
tive parameters included operation time, resection weight, 
irrigation fluid volume during the procedure, post-
operative irrigation duration, catheter duration, hospital 
stay, and hemoglobin and serum sodium levels before and 
after the operation. Patient baseline characteristics, peri-
operative data, and postoperative outcomes were com-
pared and major complications were recorded.
Conventional TUR-P was performed in 39 cases with a 
24 Fr Storz monopolar resectoscope (Karl Storz, Tuttlin-
gen, Germany) with a single wire loop and Urosol (CJ, 
Seoul, Korea). TURIS was conducted by using the Olympus 
SurgMaster UES-40 bipolar generator and a 24 Fr resecto-
scope, and saline irrigation was performed in 19 patients. 
TURIS-V procedures used the same bipolar generator, and 
the special ‘mushroom’ type vapo-resection electrode was 
used in 15 patients. This new spherical electrode displays 
a plasma corona on its surface and is gradually moved into 
direct contact with the enlarged prostatic adenoma tissue 
(the ‘hovering’ technique), thus producing virtually blood-
less vaporization at 280 W. Several prostatic fragments 
were resected for pathological analysis in conventional 
TUR-P and TURIS. Coagulation of any hemorrhagic sour-
ces was practically concomitant, while for larger vessels, 
hemostasis was achieved by reducing the power of the gen-
erator to 80 W. In all cases, a 22 Fr 3 way Foley catheter 
was placed at the end of the procedure and continuous sal-
ine irrigation was applied.
Statistical variables were analyzed with the Korean ver-
sion of SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). 
Comparison of preoperative and postoperative baseline 
values and perioperative parameters between the three 
groups was done by ANOVA test. The relationship of com-
plications to operative methods was examined by using 
Pearson chi-square tests. Postoperative follow-up outcome 
parameters according to each operation method were ana-
lyzed by Student’s t test between preoperative data and 
each scheduled follow-up time. Each statistical value was 
determined to have a significant difference when p＜0.05.
RESULTS 
Among 73 consecutive patients, the 39 patients who under-
went conventional TUR-P were 56 to 86 years old (Mean 
± SD age, 69.79±6.33), the 19 patients treated with TURIS 
were 61 to 78 years old (70.16±4.32), and the 15 patients 
who underwent TURIS-V were 61 to 91 years old (73.40± 
7.62). Average prostate volumes were 62.34±18.25 ml in 
the TUR-P group, 68.83±21.59 ml in the TURIS group, and 
61.45±21.59 ml in TURIS-V group. The PSA level of the 
TUR-P group was 3.70±2.50 ng/ml, that of the TURIS 
group was 3.82±2.52 ng/ml, and that of the TURIS-V group 
was 3.35±2.01 ng/ml. There were no statistically sig-Korean J Urol 2011;52:763-768
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TABLE 1. Baseline characteristics of the patients according to operation method
Characteristics Conventional TUR-P  TURIS TURIS-V p-value
Number
Age
Prostate volume (ml)
Serum PSA (ng/ml)
IPSS
QoL
Qmax (ml/s)
PVR (ml)
ASA score
39
69.79±6.33
  62.34±18.25
  3.70±2.50
23.77±4.41
  4.33±0.74
  8.38±3.90
  79.59±83.09
  1.44±0.55
19
70.16±4.32
  68.83±14.94
  3.82±2.52
25.26±3.31
  4.05±0.91
  8.74±2.28
    59.63±100.19
  1.79±0.42
15
73.40±7.62
  61.45±21.59
  3.35±2.01
24.47±5.10
  4.20±0.86
  8.07±3.56
    91.73±100.28
  1.80±0.41
0.153
0.382
0.845
0.462
0.462
0.855
0.577
0.12
TUR-P: transurethral resection of the prostate, TURIS: transurethral resection of the prostate in saline, TURIS-V: TURIS-plasma 
vaporization, PSA: prostate-specific antigen, IPSS: International Prostate Symptom Score, QoL: quality of life, Qmax: maximal urinary 
flow rate, PVR: postvoiding residual urine, ASA: American Society of Anesthesiologists
TABLE 2. Comparison of operative parameters, hospital courses, and postoperative complications according to operation method
Conventional TUR-P TURIS TURIS-V p-value
Operative parameter
    Operation time (min)
    Resection weight (g)
    Irrigation fluid volume during the 
      procedure (x3,000 ml)
Hospital course
    Postoperative irrigation duration (hr)
    Catheter duration (days)
    Hospital stay (days) 
Complication
    Transfusion (%)
    Clot retention (%)
73.85±29.70
12.27±8.67
9.85±3.51
38.00±13.93
4.26±0.99
6.66±1.22
3 (7.7)
  4 (10.3)
  71.84±24.96
16.87±6.64
10.05±3.37
38.26±6.00
  4.05±0.40
  6.00±0.58
1 (5.3)
1 (5.3)
58.67±28.88
7.00±3.09
24.27±5.66
2.80±0.41
4.86±0.52
0 (0)
0 (0)
0.211
 0.047
a
0.016
＜0.001
＜0.001
＜0.001
0.538
b
0.389
b
TUR-P: transurethral resection of the Prostate, TURIS: transurethral resection of the prostate in saline, TURIS-V: TURIS-plasma 
vaporization, 
a: Student’s t-test, 
b: Pearson chi-square test
TABLE 3. Comparison of changes in hemoglobin and serum sodium levels before and after the operation according to operation method
Conventional TUR-P TURIS TURIS-V p-value
Hemoglobin decrease (mg/dl)
Serum sodium decrease (mmol/l)
−0.77±1.33
−0.05±3.30
−0.71±1.09
1.46±3.42
−0.19±1.14
−0.50±3.06
0.302
0.165
TUR-P: transurethral resection of the prostate, TURIS: transurethral resection of the prostate in saline, TURIS-V: TURIS-plasma 
vaporization
nificant differences among the 3 groups in baseline param-
eters (Table 1).
The mean operation times were 73.85±29.70 minutes, 
71.84±24.96 minutes, and 58.67±28.88 minutes in the 
TUR-P group, the TURIS group, and the TURIS-V group, 
respectively. Although TURIS-V showed the shortest oper-
ation time, the differences between the groups were not 
statistically significant. The mean amount of prostatic tis-
sue (±SD) resected was 12.27±8.67 g in the TUR-P group 
and 16.87±6.64 g in the TURIS group (p=0.047). TURIS-V 
significantly decreased irrigation fluid volume during the 
operation in comparison with conventional TUR-P and 
TURIS (p=0.016) and also significantly decreased post-
operative irrigation duration, catheter duration, and hos-
pital stay (all p＜0.001) (Table 2). There were three trans-
fusions and four clot retentions in the TUR-P group, and 
one transfusion and one clot retention in the TURIS group. 
There were no complications in the TURIS-V group. There 
were no significant differences across the three groups in 
changes to hemoglobin and serum sodium levels before and 
after the operations (Table 3). 
The follow-up data are presented in Fig. 1. All patients 
completed 6 months of follow-up. Compared with baseline, 
there were significant improvements in IPSS, QoL, Qmax, 
and postvoiding residual urine after surgery in all groups. Korean J Urol 2011;52:763-768
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FIG. 1. Postoperative follow-up outcome parameters according to the operation methods: transurethral resection of the prostate 
(TUR-P), transurethral resection of the prostate in saline (TURIS), and TURIS-plasma vaporization (TURIS-V). (A) International 
Prostate Symptom Score (IPSS), (B) quality of life (QoL), (C) Maximal urinary flow rate (Qmax), (D) postvoiding residual urine (PVR), 
a: p＜0.01, 
b: p＜0.05, 
c: p＞0.05 (preoperative value vs. present value, Student’s t-test).
DISCUSSION
In the past 10 to 15 years, most men diagnosed with BPH 
were primarily treated medically, commonly with α-adre-
nergic blockers. Despite the availability of medical treat-
ment, a significant proportion of BPH patients require sur-
gical intervention, for which the available options range 
from minimally invasive techniques to open procedures. 
When the side effects of pharmacotherapy, such as dry 
mouth and orthostatic hypotension, are severe, patients 
may choose surgical treatment instead [10]. Surgical treat-
ment is more effective in improving LUTS and urinary flow 
rate than is medical treatment [11]. 
In Korea during 2004 to 2008, over 3.8 million men vis-
ited clinics and were prescribed one or more BPH medi-
cations, and more than 44,000 men underwent surgical 
treatment. Compared with the year 2004, the number of 
TUR-P cases increased by a factor of 1.2 in 2008. Before 
2006, TUR-P was the most commonly used surgical option, 
but laser therapy such as KTP vaporization for the treat-
ment of BPH has been carried out at levels similar to TUR-P 
since then [12]. According to a recent online survey in the 
United States, the percentages of urologists performing 
the various types of BPH surgery are as follows: monopolar 
TUR-P, 73%; photoselective vaporization of the prostate 
(PVP), 58%; TURIS-V, 24%; bipolar TUR-P, 20%; holmium 
laser ablation of the prostate, 18%; thulium laser ablation 
of the prostate, 4%; and laparoscopic and robotic simple 
prostatectomy, 1% and 3% [13].
TUR-P has been considered the gold standard for the sur-
gical treatment of BPH for many years [4]. However, the 
morbidity after TUR-P is significant [4,14]. In the past dec-
ade, several technologies have been developed to treat BPH 
with minimal risks and acceptable efficacy. Recently, the 
use of bipolar electrosurgical technology, TURIS, has 
shown lower complication rates and comparable results to 
standard TUR-P [8,15]. Additionally, the use of 0.9% saline 
as the irrigation fluid has greatly reduced the risk of TUR 
syndrome, owing to reduced fluid absorption [9]. Bipolar 
electrosurgical technology made transurethral elec-
tro-vaporization increasingly popular, especially after the 
development of the Gyrus PlasmaKinetic (PK) Tissue 
Management System (Gyrus Medical Ltd, Bucks, UK). 
Several studies involving plasma vaporization using the 
Plasma Kinetic Tissue Management System have been 
performed in recent years to compare the method with 
standard TUR-P in a prospective, randomized fashion. 
Hon et al reported that this technique was as effective as Korean J Urol 2011;52:763-768
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TUR-P for BPH, because it provided good long-term results 
and incurred fewer early complications [16]. A study by 
Karaman et al determined favorable outcomes for plasma 
kinetic vaporization of the prostate during a 1-year fol-
low-up [17]. Another study by Patankar et al described the 
PK Superpulse system, which provides faster removal of 
tissue, in a bloodless field and with better views and a safer 
environment of saline irrigation, and with an efficacy com-
parable to that of conventional TUR-P [18].
TURIS-V, using the Olympus
Ⓡ UES-40 Surgmaster gen-
erator (Olympus, Tokyo, Japan) and the ‘mushroom’ va-
po-resection electrode, was recently introduced in clinical 
practice. The basis of TURIS-V is represented by the ability 
of the UES-40 bipolar electrosurgical generator to produce 
a plasma corona on the surface of the spherical or 
‘mushroom’ shaped electrode. Plasma vaporization occurs 
by direct, gentle contact with the tissue surface and per-
forms concomitant hemostasis. TURIS-V is associated 
with less bleeding during surgery than TUR-P. It also se-
cures a better endoscopic view and less hematuria after 
surgery and improves the Foley catheter maintenance 
period. Vapo-resection brings about a remarkably smooth 
surface and sharp margins, with few irregularities or de-
bris, and no supplementary thermal injury to the subjacent 
tissue. Due to the lack of bleeding, visibility remains ex-
cellent throughout the operation. 
The merits of TURIS-V, including fast vaporization, con-
comitant hemostasis, and quick evacuation of the few re-
sected tissue fragments, result in a significantly reduced 
operation time and increased efficacy of operations on the 
prostate [19]. Recently, TURIS-V was shown to represent 
a valuable endoscopic treatment alternative for patients 
with BPH, with superior efficacy, short-term results, and 
complication rates compared with monopolar TUR-P [19].
The present study showed that TURIS-V had the short-
est operation time in comparison with conventional TUR-P 
and TURIS, but this difference had no statistical sig-
nificance (p=0.211). However, TURIS-V significantly de-
creased the irrigation fluid volume used during the proce-
dure in comparison with conventional TUR-P and TURIS. 
TURIS-V also significantly decreased postoperative irri-
gation duration, catheter duration, and the length of hospi-
tal stay. 
With regard to the postoperative complications in this 
study, there was no significant difference in the changes 
in hemoglobin levels or serum sodium levels before and af-
ter surgery among the three groups. The TURIS-V group 
had no specific complications, but there were three trans-
fusions and four clot retentions in the TUR-P group, and 
one transfusion and one clot retention in the TURIS group. 
There were no differences among the three groups in terms 
of IPSS, QoL, uroflowmetry, or residual urine during the 
follow-up period at 1, 3, and 6 months postoperatively, dem-
onstrating the comparable efficacy of the three techniques. 
In addition, significant improvements in the subjective 
and objective voiding parameters were achieved in all 
groups, and these improvements were sustained for the pe-
riod under observation. 
In Korea, laser therapy such as KTP vaporization for the 
treatment of BPH has been carried out as frequently as 
TUR-P since 2006 [12]. The Korea health care system ap-
plies similar medical insurance fees to TUR-P and PVP. 
The medical insurance fee of TURIS-V is equal to that of 
TUR-P in Korea. The treatment effects of TURIS-V are sim-
ilar to those of TUR-P, and the safety of TURIS-V is similar 
to that of PVP by laser. However, TURIS-V may be more 
cost-effective than PVP by laser owing to the relative prices 
of the system equipment.
This study had the limitations of being a retrospective 
observational study with a small sample size, which im-
posed limitations on statistical power. However, we know 
there are few reports about the efficacy and safety of 
TURIS-V in Korea. This pilot study showed the trends that 
TURIS-V significantly improved objective and subjective 
urination symptoms, even in patients with prostate vol-
umes of 60 ml or more. TURIS-V significantly decreased 
the irrigation fluid volume used during the operations in 
comparison with conventional TUR-P and TURIS and also 
significantly decreased postoperative irrigation duration, 
catheter duration, and hospital stay. Further studies of the 
efficacy and safety of TURIS-V are warranted to explore 
and validate the benefits for urologists. 
CONCLUSIONS
In this pilot study, we confirmed that TURIS and TURIS-V 
were effective surgical treatments for BPH in addition to 
conventional TUR-P, and TURIS-V was not inferior to con-
ventional TUR-P and TURIS for safety. TURIS-V repre-
sents a promising endoscopic treatment alternative for pa-
tients with BPH, showing good efficacy, reduced morbidity, 
fast recovery, and satisfactory follow-up. Our results sug-
gest that further studies with a prospective randomized de-
sign and a long-term follow-up are warranted.
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